PMCB

PharmaCyte is a clinical-stage cancer-therapy shell whose entire business case rests on a single IND that has been on FDA clinical hold since October 30, 2020 — nearly six years — with no lifting disclosed. Revenue has been exactly $0.00 every year from FY2021 through FY2025, and the company spent just $438K on R&D last year, a trivial figure for a firm that claims to be 'preparing to commercialize cellular therapies.' Operationally it is loss-making (operating income -$4.38M) and cash-consuming (operating cash flow -$2.98M), and its cash pile fell 69.8% to $15.2M while current assets collapsed 55.6%. This is not a going concern strengthening; it is a runway shrinking.

The seductive headline numbers — net income $30.7M, diluted EPS $3.19, a 0.2x P/E, ROE 59.1% — are accounting artifacts, not earnings. With zero revenue and a -$4.38M operating loss, the entire $30.7M 'profit' comes from non-operating/fair-value items (the filing references a 'TNF Transaction' and the Series B preferred/warrant machinery), and the -$85.0M accumulated deficit confirms there has never been real profitability. Valuing this stock on that P/E is meaningless; it will not recur.